Characteristics of ALL and AML samples and transduction efficiency
| Sample no. . | FAB . | Immunophenotype . | Cytogenetic findings . | % transduction . |
|---|---|---|---|---|
| ALL 1 | L2 | 45,19,10,20,13,34,38,TdT-positive | −14,+12p | 40.3 |
| ALL 2 | L2 | 45,19,10,20,HLA-DR,33,TdT-positive | bcr/abl-p210 | 90.3 |
| ALL 3 | L2 | 45,19,10,20,38,TdT-positive | t(1:19) | 63.9 |
| ALL 4 | L1 | 19,10,20,HLA-DR,34,38,TdT-positive | Normal | 84.5 |
| ALL 5 | L2 | 19,10,HLA-DR,34,38,TdT-positive | Not available | 42.6 |
| AML 1 | M4 | 13,33,34,TdT-negative | Not available | 75.4 |
| AML 2 | M2 | 13,33,34,HLA-DR,TdT-negative | t(6:9) | 61.7 |
| AML 3 | M4 | 13,33,HLA-DR,TdT-negative | t(8:21) | 87.6 |
| AML 4 | M4 | 33,4,TdT-negative | Not available | 84.2 |
| AML 5 | M4 | 33,65,TdT-negative | t(11:19) | 79.1 |
| Sample no. . | FAB . | Immunophenotype . | Cytogenetic findings . | % transduction . |
|---|---|---|---|---|
| ALL 1 | L2 | 45,19,10,20,13,34,38,TdT-positive | −14,+12p | 40.3 |
| ALL 2 | L2 | 45,19,10,20,HLA-DR,33,TdT-positive | bcr/abl-p210 | 90.3 |
| ALL 3 | L2 | 45,19,10,20,38,TdT-positive | t(1:19) | 63.9 |
| ALL 4 | L1 | 19,10,20,HLA-DR,34,38,TdT-positive | Normal | 84.5 |
| ALL 5 | L2 | 19,10,HLA-DR,34,38,TdT-positive | Not available | 42.6 |
| AML 1 | M4 | 13,33,34,TdT-negative | Not available | 75.4 |
| AML 2 | M2 | 13,33,34,HLA-DR,TdT-negative | t(6:9) | 61.7 |
| AML 3 | M4 | 13,33,HLA-DR,TdT-negative | t(8:21) | 87.6 |
| AML 4 | M4 | 33,4,TdT-negative | Not available | 84.2 |
| AML 5 | M4 | 33,65,TdT-negative | t(11:19) | 79.1 |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; and FAB, French-American-British leukemia classification.